Patent Publication Number: US-2023134529-A1

Title: Labisia pumila extract composition and its pharmaceutical formulation

Description:
FIELD OF THE INVENTION 
     The present invention relates to  Labisia pumila  extract composition and its pharmaceutical formulation for reducing the progression of health problems and for the treatment of diseases and process for preparation thereof and their uses as pharmaceutical and nutraceutical bioactive that treats metabolic syndrome, inflammatory diseases, and hormonal imbalances. More particularly, the present invention relates to corresponding process and to certain novel  Labisia pumila  extract composition with pharmaceutical grade safety standard and its optimised and stable pharmaceutical dosage form for clinical use. 
     BACKGROUND OF THE INVENTION 
       Labisia pumila  is an herbaceous plant found in the lowlands and forests of Southeast Asia, particularly Malaysia, Indonesia, Thailand, Laos, Cambodia, and Vietnam. It is a slow growing plant and propagates by its rhizomes, leaves, and seeds. The plant grows wild at 80-100 meters above sea level but can also be cultivated.  Labisia pumila  is believed to have phytoestrogen acting as primary female sex hormone, particularly estrogen. This is because the plant is widely used as woman post-partum medicine traditionally (Abdullah et al., 2013). There is now an increasing demand for the supply of “kacip fatimah’ ( Labisia pumila  syn.  Labisia pothoina ) in the food industries, the reproducibility of extraction processes is still in doubt due to the lack of reliable chemical profiling methods. 
     Prior art U.S. Pat. No. 7,879,368 disclosed a process for preparation of  Labisia pumila  extract by extracting dried  Labisia pumila  plant material with water at a ratio of 1:6 of dried  Labisia pumila  plant material:water to form a water-soluble extract and drying the extract wherein the extracting is carried out at 80° C. for 3 hours and with continuous stirring. Optionally wherein the extraction process is repeated and the ratio of  Labisia pumila  plant material:water is 1:6; optionally wherein the  Labisia pumila  extract is dried and concentrated by spray-drying; optionally wherein the spray-drying is performed using a spray tower having a tower inlet and outlet, and wherein tower inlet temperature is 185° C. and wherein tower outlet temperature is 107° C., respectively. 
     Meanwhile another prior art, U.S. Pat. No. 9,358,260 disclosed a process for obtaining a  Labisia pumila  extract comprising the steps of obtaining an extract from dried  Labisia pumila  plant material using water extraction, filtering the extract to obtain filtrate and  Labisia pumila  plant material residue, re-extracting the  Labisia pumila  residue using water extraction, centrifuging the  Labisia pumila  extracts to obtain a supernatant, characterized in that the  Labisia pumila  plant material includes leaves and roots in a ratio of 3:2 by weight and ratio of the dried plant material to water used in the water extraction process is 1:10 by weight. The process for obtaining a  Labisia pumila  extract, the dried  Labisia pumila  plant material is extracted through water extraction using distilled water or reverse osmosis water or deionised water, wherein the water is used as a solvent during the extraction process to produce higher quality of extract. The quantity ratio of dried plant material to the solvent is preferably one part of dried plant material to ten parts of solvent. In a preferred embodiment of the process for obtaining a  Labisia pumila  extract, the water extraction is performed at a temperature of 80° C. for three hours with stirring to obtain uniform extract. In the next step, the extract is filtered to obtain filtrate and  Labisia pumila  plant material residue. The  Labisia pumila  residue is re-extracted using water extraction. In a preferred embodiment, the residue is re-extracted with the same volume of water used in the initial extraction and re-extracted at a temperature of 80° C. for an hour with stirring. The  Labisia pumila  extracts is then centrifuged to obtain the supernatant. In a preferred embodiment of the process for obtaining a  Labisia pumila  extract, the centrifuging is conducted at 3500 rpm for 15 minutes. In a preferred embodiment of the process for obtaining a  Labisia pumila  extract, the supernatant is further filtered and concentrated using rotary evaporator at temperature of 75° C. to evaporate the excessive solvent from the supernatant. The supernatant is filtered using Buchner Funnel. In a preferred embodiment of the process for obtaining a  Labisia pumila  extract, the supernatant is freeze-dried to obtain powdery residue. The supernatant is transferred into a freeze dryer vessel and frozen in a freezer at −20° C. The frozen extract is then dried in a freeze dryer until a powdery residue is obtained. 
     WO2013112040A1 disclosed the a method for producing a plant extract formulation according to claim  7 , comprising the following steps: (i) providing a plant or a part of a plant of the family Myrsinaceae, preferably from the genus  Labisia , more preferably from  Labisia pumila , particularly preferably from the roots of  Labisia pumila , (i-a) optionally drying the plant or a part of a plant of step (i), (ii) extraction of said plant or a part of a plant provided in step (i) or (i-a) with a mixture of water and an alcohol having 1 to 3 carbon atoms, preferably with a mixture of ethanol and water, wherein the volume ratio (v/v) of said alcohol:water in the range of 1:2 to 30:1, more preferably in the range of 1:1 to 25:1, most preferably in the range of 3:2 to 20:1, (ii-a) optionally partially or fully removing the alcohol having 1 to 3 carbon atoms of step (ii), preferably at a temperature below 70° C., more preferably in the range from 15 to 55° C., (iii) mixing the extract obtained in step (ii) or (ii-a) with one or more solid carrier substances, preferably one or more solid carrier substances selected from the group consisting of maltodextrins, silica, talc, lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, orally acceptable stearate salts, preferably magnesium stearate, alginates, tragacanth, gelatins, calcium silicates, cellulose and cellulose derivatives, preferably microcrystalline cellulose or methyl cellulose, polyvinylpyrrolidones, and propylhydroxybenzoates, (iv) optionally drying the mixture obtained in step (iii), preferably by spray-drying or freeze-drying. 
     Another prior art, WO2016093692A1 disclosed a process to obtain an extract of  Labisia pumila  comprising: i. obtaining a  Labisia pumila  plant sample; ii. reducing the water content of the plant sample to provide a dried sample; iii. subjecting the dried sample to extraction with a solvent containing a mixture of an alcohol and water to provide an alcoholic extract; and iv. removing the solvent from the alcoholic extract to obtain the extract of  Labisia pumila . The plant sample may be derived from the leaves of a  Labisia pumila  plant, optionally the plant sample may be additionally or alternatively derived from the roots and/or stems of a  Labisia pumila  plant. In further embodiments, reducing the water content in step (ii) is performed for from 24 hours to 72 hours at from 40° C. to 60° C. For example, reducing the water content can be performed for 72 hours at 55° C. In certain embodiments, the dried sample is ground into a powder before use in step (iii). In yet further embodiments, extraction step (iii) may comprise the use of a soxhlet extracting technique. The solvent containing a mixture of an alcohol and water is replaced at least once to form at least two alcoholic extracts that are combined together. In yet further embodiments, extraction step (iii) may be performed for from 5 hours to 240 hours. For example, the extraction step is performed for 120 hours. The solution containing a mixture of an alcohol and water may have a volumetric ratio (alcohol:water) of from 4:1 to 1:4 (e.g. the volumetric ratio may be 1:1). In yet still further embodiments, the step of removing the solvent from the alcoholic extract in step (iv) may be performed by spray drying, freeze drying or evaporation. 
     Accordingly, it can be seen from the prior art that there is a need to provide an optimized extraction process of  Labisia pumila  plants that will give optimised stability, higher yield, quality, safety and efficacy of the  Labisia pumila  extract, and also an optimized pharmaceutical dosage formulation that are stable, safe and efficacious for clinical use. 
       Labisia pumila  is typically boiled and the water-soluble extract is taken as a drink. While it is most extensively used during childbirth and the postpartum period,  Labisia pumila  is used by both men and women for a variety of other conditions. There is no documentation in the literature regarding the recommended or practical frequency or dose of use in any population.  Labisia pumila  is widely available in Malaysia in supplements, traditional medicines, teas, and cosmetic products, but the overall use level is not well documented. It also cannot be determined from publicly available information how much  Labisia pumila  extract is contained in each product nor at what level individual chemical components are present in these extracts. 
     WO2013112040A1 disclosed the  Labisia pumila  extracts is used for the cosmetic prevention, treatment or reduction of cellulite, and/or for the non-therapeutic, preferably cosmetic, reduction of the lipid quantity contained in subcutaneous fat tissue, and/or inhibition of the differentiation of preadipocytes, and/or inhibition of the lipogenesis in adipocytes, and/or as cosmetic anti-cellulite active. Plant extract formulation, preferably in solid form, obtainable from a plant of the family Myrsinaceae, preferably from the genus  Labisia , more preferably from  Labisia pumila , particularly preferably from the roots of  Labisia pumila , comprising (a) one or more compounds of formula (I) as defined in claim  5  or a physiologically acceptable salt thereof in a total amount effective, preferably the total amount being in the range from 0.1 to 15 wt. %, more preferably from 0.2 to 10 wt. %, particularly preferably from 0.5 to 6 wt. %, most preferably from 1 to 5 wt. %, most preferably from 1.25 to 4 wt. %, based on the total weight of the plant extract formulation, (b) one or more further substances naturally occurring in said plant from, wherein said one or more further substances are not compounds of formula (I) as defined in claim  5  or a physiologically acceptable salt thereof, and (c) one or more solid carrier substances, preferably one or more solid carrier substances selected from the group consisting of maltodextrins, silica, talc, lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, orally acceptable stearate salts, preferably magnesium stearate, alginates, tragacanth, gelatins, calcium silicates, cellulose and cellulose derivatives, preferably microcrystalline cellulose or methyl cellulose, polyvinylpyrrolidones, and propylhydroxybenzoates. 
     While, the prior art WO2016093692A1 disclosed a pharmaceutical formulation comprising an extract of  Labisia pumila  and/or a nano-formulated liposome extract of  Labisia pumila  in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier for use in the manufacture of a medicament for the treatment of obesity. WO2009116848A1 revealed that the use of standardised aqueous extract of  Labisia pumila  in orally sufficient amount characterised in that said extract reduces the risk or progression of cardiovascular diseases and age-related health problems wherein the amount of extract orally taken ranges from 100-500 mg/day. The extract influences pathophysiological changes, including regulation of genes associated with insulin resistance, obesity, metabolic syndrome, diabetes and aging. However, it is unclear the main phytochemical components extracted from  Labisia pumila  which contributed to each medical treatment. 
     In view of the above shortcomings, the present invention aims to provide new  Labisia pumila  extract composition for reducing the progression of health problems and diseases and an improvement process for preparation thereof and their uses. In addition, the present invention discloses an improvement novel compound of  Labisia pumila  extract composition for pharmaceutical formulation and dosage form with improved stability in storage, including shelf-life and their useable, efficacious and safe administration for clinical use. 
     SUMMARY OF THE INVENTION 
     The present invention provides a process for obtaining a  Labisia pumila  extract composition comprising the steps of: extracting dried  Labisia pumila  plant of material with a solvent at a ratio of between 1:5 to 1:20-respectively in weight/volume at a temperature of 60-100° C. for 2-6 hours in an extraction chamber to obtain a first extract; filtering the first extract to obtain a first filtrate and a plant residue; re-extracting the plant residue with the solvent at a temperature of 60-100° C. for 2-6 hours in the extraction chamber to obtain a second extract; filtering the second extract to obtain a second filtrate and the plant residue; concentrating the first extract and the second extract; mixing the first concentrated extract and the second concentrated extract to form the  Labisia pumila  extract; homogenizing the  Labisia pumila  extract with maldodextrins into the  Labisia pumila  extract composition; and spray-drying the  Labisia pumila  extract composition. 
     In another embodiment of the present invention, the dried  Labisia pumila  plant of material is prepared by the following steps
         (i) drying leaves of the  Labisia pumila  plant at 40-55° C. until a moisture content is 6-8%;   (ii) drying stems and roots of the  Labisia pumila  plant at 40-55° C. until a moisture content is 6-8%;   (iii) grounding the dried leaves, stems and roots of the  Labisia pumila  plant to a particle size of 2-4 mm.       

     In yet another embodiment of the present invention, the solvent is water and ethanol at a volumetric ratio of 1:1. 
     In yet another embodiment of the present invention, the concentrating for the first extract is performed at a temperature of 80° C., pressure at 0.02 MPa in a concentration chamber. 
     In another embodiment of the present invention, the concentrating for the second extract is performed at a temperature of 80° C., pressure at 0.02 MPa for in a concentration chamber. 
     In yet another embodiment of the present invention, the spray-drying is performed at an inlet temperature of 150-170° C. and an outlet temperature of 80-110° C. with a feed pump flow rate of 35-50 RPM. 
       Labisia pumila  extract composition obtainable from the process of the present invention is  Labisia pumila  aqueous ethanolic extract. A  Labisia pumila  extract composition characterized in that it produces 27 peaks in positive ion mode when subjected to LC-MS/MS chromatography and produces 27 peaks in negative ion mode when subjected to LC-MS/MS chromatography. These 27 constituents were positively identified in LC-MS/MS chromatography, including various flavonoids, phenolic acids, and fatty acids ( FIG.  4   ). The chemical fingerprints showing the overall composition of this complex botanical extract are shown in  FIG.  6    (positive ionization mode) and  FIG.  7    (negative ionization mode). 
     Standardised  Labisia pumila  aqueous ethanolic extract in orally effective amount characterised in that said extract for reducing the progression of problems selected from obesity. In another embodiment of the present invention, standardised  Labisia pumila  aqueous ethanolic extract for use wherein the effective and safe amount of extract orally taken ranges from 180 mg/day to 1500 mg/day for a period of between 7 days to more than 12 months. In another embodiment of the present invention, standardized  Labisia pumila  aqueous ethanolic extract for use wherein the extract reduces the progression of health problems selected from obesity in humans. In yet another embodiment of the present invention, standardized  Labisia pumila  aqueous ethanolic extract for use wherein the extract reduces the progression of health problems selected from obesity, metabolic syndrome, anti-inflammatory and antioxidant treatment. 
     A  Labisia pumila  extract comprises one or more extract components of flavonols; flavanols; flavanones; flavones; hydroxybenzoic acids; hydroxycinnamic acids; phenolic alcohols; organic acids; vitamins and vitamin precursors; saponins; alkylphenols; and fatty acids. In one of the embodiments of the present invention, the flavonols comprises myricetin, quercetin and rutin. In another embodiment of the present invention, the flavanols comprises catechin and epigallocatechin. In yet another embodiment of the present invention, the flavanones comprises naringenin. In another embodiment of the present invention, the flavones comprises apigenin. In another embodiment of the present invention, wherein the hydroxybenzoic acids comprises methyl gallate, protocatechuic acid, salicylic acid, syringic acid and vanillic acid. In yet another embodiment of the present invention, the hydroxycinnamic acids comprises caffeic acid and m-coumaric acid. In yet another embodiment of the present invention, the phenolic alcohols comprises pyrogallol. In another embodiment of the present invention, the organic acids comprises fumaric acid and succinic acid. In yet another embodiment of the present invention, the vitamins and vitamin precursors comprise ascorbic acid. In another embodiment of the present invention, the saponins comprises ardisiacrispin A and ardisicrenoside A. In another embodiment of the present invention, wherein the alkylphenols comprises irisresorcinol and the fatty acids comprises α-linolenic acid, linoleic acid, oleic acid, palmitic acid and stearic acid. The  Labisia pumila  extract further having antioxidant properties of 65-92% of 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity and the average total phenolic content (TPC) was more than 100 mg gallic acid equivalents (GAE)/g. 
     A pharmaceutical formulation comprising a  Labisia pumila  extract in admixture with a pharmaceutically acceptable carrier for reducing the progression of health problems selected from obesity. In one of the embodiments of the present invention, the pharmaceutical formulation wherein the acceptable carrier is maltodextrins and other excipients. In yet another embodiment of the present invention, the  Labisia pumila  extract is a  Labisia pumila  aqueous ethanolic extract. The pharmaceutical formulation is formulated as an oral effective dose for acceptable daily intake of 180 mg/day to 1500 mg. A delivery system for orally administering the pharmaceutical formulation wherein the delivery system comprises tablets, capsules, pills, granules, syrups, powders, concentrates or dry syrups. 
     One of the advantages of process of the extraction is having shorter duration extraction compared to the prior art documents. In addition, the  Labisia pumila  extract can be stored at least 3 years shelf-life with improved stability in storage, including shelf-life and their useable administration. Another advantage of the pharmaceutical formulation of the present invention is an improved formulation with pharmaceutical grade safety standard, and its optimised and stable pharmaceutical dosage form for clinical use and for obesity, metabolic syndrome, anti-inflammatory, treatment from 180 mg/day to 1500 mg/day for a period of 7 days to more than 12 months. 
     Another advantage of the method of the present invention is that 
     a. ghrelin levels were significantly reduced in animals treated with  Labisia pumila  extract composition 77.5 mg/kg, SKF7™ 155 mg/kg,  Labisia pumila  extract composition 310 mg/kg groups as compared to DIO control group by 18.0% (P≤0.05), 44.5% (P≤0.01), 39.5% (P≤0.01) and, respectively. Weight loss induce significant increases in the concentration of ghrelin, a potent orexigenic hormone. Elevations in ghrelin concentration, either endogenous or exogenous, are associated with feelings of hunger and increased food intake. Interestingly,  Labisia pumila  extract composition inhibits ghrelin production levels while inducing weight loss. Hence, no significant changes were observed in average daily feed consumption in all groups.
 
b. Proven safe in subchronic and chronic toxicology studies (and other toxicology studies).
 
     Further advantages of the system in accordance with the invention and its application can be derived from the description and the accompanying drawings. The above-mentioned features and those to be further described below can be utilized in accordance with the invention individually or collectively in arbitrary combination. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
       The accompanying drawings, which are incorporated in and constitute a part of the specification, illustrate embodiments of the invention and, together with the description, serve to explain the principles of the invention. 
         FIG.  1    illustrates processing steps and quality control parameters (QCPs) for  Labisia pumila  raw plant material in accordance of the present invention. 
         FIG.  2    illustrates manufacturing process and quality control parameters (QCPs) to produce SKF7™ extract in accordance of the present invention. 
         FIG.  3    illustrate steps, methods, and materials, used in the production of SKF7™ in accordance of the present invention. 
         FIG.  4    illustrates phytochemicals positively identified in SKF7™ extract using LC-MS/MS in accordance of the present invention. 
         FIG.  5    illustrates SKF7 with Gallic Acid assay chromatogram and quantification (validated HPLC method, Retention time ˜3.7 min) in accordance of the present invention. 
         FIG.  6    illustrates overlay of SKF7™ LC-MS/MS Chromatograms in positive ion mode in accordance of the present invention. 
         FIG.  7    illustrates overlay of SKF7™ LC-MS/MS Chromatograms in negative ion mode in accordance of the present invention. 
         FIG.  8    illustrates In vivo study was conducted on SKF7™ treated rats, comparing to normal rat and Diet-Induced Obese (DIO) rats for anti-inflammatory treatment in accordance of the present invention. 
         FIG.  9    illustrates In vivo study was conducted on SKF7™ treated rats, comparing to normal rat and Diet-Induced Obese (DIO) rats for anti-oxidant treatment in accordance of the present invention. 
         FIG.  10    illustrates In vivo study was conducted on SKF7™ treated rats, comparing to normal rat and Diet-Induced Obese (DIO) rats for suppression of Ghrelin production levels in accordance of the present invention. 
     
    
    
     DETAILED DESCRIPTIONS OF THE INVENTION 
     The present invention will now be described in detail in connection with specific embodiments with reference to the accompanying drawings. Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense that is as “including, but not limited to”. Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity. It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or “B” or “A and B.” Further, terms such as “first,” “second,” “third,” etc., merely identify one of several portions, components and/or points of reference as disclosed herein, and do not limit the present invention to any particular configuration or orientation. 
     The term “shelf life” refers to the amount of time the pharmaceutical composition may be stored without loss of potency and/or performance profile. 
     By the term “extract”, either a direct extract (in liquid or preferably dried form), e.g. obtained as described below, or preferably a further enriched extract (obtainable e.g. by one or more further purification steps after extraction, e.g. chromatography, for example as described below) containing one or more, preferably two or more compounds. 
     “Obtainable” means that a product (e.g. extract or compound) may be obtained by a certain method, and preferably is obtained by said process. 
     By “administered” or “administering” herein is meant administration of a prophylactically and/or therapeutically effective dose of a compound of  Labisia pumila  extract or a mixture of compounds of  Labisia pumila  extract, or an extract comprising one or more the compounds of  Labisia pumila  extract, to a human being in need of such treatment. 
     By “effective amount” or “effective dose” herein is meant an amount or a dose that produces the (therapeutic or cosmetic) effect for which it is administered. 
     The term “SKF7™” used throughout the entire patent specification is a tradename of  Labisia pumila  extract composition either a direct extract (in liquid or preferably dried form), e.g. obtained as described below, or preferably a further enriched extract (obtainable e.g. by one or more further purification steps after extraction, e.g. chromatography, for example as described below) containing one or more, preferably two or more compounds. 
     The present invention relates to corresponding process and to certain novel compounds of  Labisia pumila  extract composition for pharmaceutical formulation. Prior to preparation of the  Labisia pumila  extract, the dried  Labisia pumila  plant of material of the present invention is prepared by the following steps 
     (i) drying leaves of the  Labisia pumila  plant at 40-55° C. for 5 hours until a moisture content is 6-8%;
 
(ii) drying stems and roots of the  Labisia pumila  plant at 40-55° C. for 6 hours until a moisture content is 6-8%; and
 
(iii) grounding the dried leaves, stems and roots of the  Labisia pumila  plant to a particle size of 2-4 mm.
 
     The present invention is further explained by the following examples. The specific examples which follow illustrate the methods in which the compositions of the present invention may be prepared, components therein and their use, as well as other embodiments of the invention, but are not to be construed as limiting the invention in scope. 
     Example 1 
     Prior to extraction, the selected  Labisia pumila  plant material was examined for appearance, organoleptic characteristics, and the presence of foreign matter. After the initial assessment, the plants were sorted (leaves, stems, roots) and washed with water. Plants were then arranged by hand in a drying oven. Drying is performed at 40-55° C. (stems and roots). The resulting moisture content was 6-8%. Dried plants were grounded to a final particle size of 2-4 mm. Ground plant materials was tested for moisture level, heavy metals, and general microbial contaminants as shown in  FIG.  1   . Materials fulfil all specifications were labelled and stored under ambient conditions (75% relative humidity, &lt;30° C.) until further processing. Storage was performed for no longer than one week. 
     A process for obtaining a  Labisia pumila  extract composition comprising the steps of: 
     (i) extracting dried  Labisia pumila  plant of material with a solvent at ratio of 1:5 to 1:20 respectively in weight/volume at a temperature of 60-100° C. for 2-6 hours in an extraction chamber to obtain a first extract;
 
(ii) filtering the first extract to obtain a first filtrate and a plant residue;
 
(iii) re-extracting the plant residue with the solvent at a temperature of 60-100° C. for 2-6 hours in the extraction chamber to obtain a second extract;
 
(iv) filtering the second extract to obtain a second filtrate and the plant residue;
 
(v) concentrating the first extract and the second extract;
 
(vi) mixing the first concentrated extract and the second concentrated extract to form the  Labisia pumila  extract;
 
(vii) homogenizing the  Labisia pumila  extract with maldodextrins into the  Labisia pumila  extract composition; and
 
(viii) spray-drying the  Labisia pumila  extract composition.
 
     The solvent used in the present invention is water and ethanol at a volumetric ratio of 1:1. The concentrating for the first extract is performed at a temperature of 80° C., pressure at 0.02 MPa in a concentration chamber. In another embodiment of the present invention, the concentrating for the second extract is performed at a temperature of 80° C., pressure at 0.02 MPa for in a concentration chamber. The spray-drying is performed at an inlet temperature of 150-170° C. ° C. and an outlet temperature of 80-110° C. with a feed pump flow rate of 35-50 RPM. 
     The  Labisia pumila  extract composition obtainable from the process of the present invention is  Labisia pumila  aqueous ethanolic extract. 
     The present invention is further explained by the following examples. The specific examples which follow illustrate the methods in which the compositions of the present invention may be prepared, components therein and their use, as well as other embodiments of the invention, but are not to be construed as limiting the invention in scope. 
     Example 2 
     The extraction process was performed at an extraction plant.  Labisia pumila  extract composition of the present invention was labelled as SKF7™ and produced in accordance with current Good Manufacturing Practices (cGMP). A general flow chart of the production process for SKF7™ extract is shown in  FIG.  2   . Extraction was performed using a 1:1 mixture of water and ethanol as the solvent. The water used for extraction was filtered and deionized.  L. pumila  whole parts or a combination of stems, leaves and/or roots were used. Ten parts solvent mixture and 1 part plant material (v/w) were placed in the extraction chamber. Extraction proceeds for 5 hours at 80° C. After this cycle, the liquid extract (Extract 1) was separated from the plant residue by filtration and sent to the concentration chamber. Fresh solvent was added to the extraction residue and another extraction cycle (5 hours at 80° C.) was performed. The resulting extract (Extract 2) was separated from the plant residue by filtration and sent for concentration. The remaining residue was discarded. 
     Extract 1 was used in the first concentration cycle. Concentration proceeds at 80° C. under 0.02 MPa pressure, for 50 minutes (Concentrate 1). Concentrate 1 was then moved to the storage tank and held at 4° C. until mixing. Extract 2 was added to the chamber and concentrated at 80° C. under 0.02 MPa pressure, for 80 minutes (Concentrate 2). Once both extracts had been concentrated, they were mixed. The combined liquid concentrate was mixed with maltodextrin powder using a homogenizer until homogeneous. The mixture was then spray dried, and the dried extract collected from the chamber. Final quality control testing was performed on the spray dried extract and includes particle size, moisture, residual alcohol, gallic acid and/or other compounds, pesticides, heavy metals, and microbial contamination and other toxins or contaminants. The steps, methods, and materials used in the production of SKF7™ were described in  FIG.  3   . Final products were packaged and stored at 15-25° C. for up to 3 years for manufacturing of the final commercial product. To ensure a consistent product, each batch of SKF7™ is evaluated against an established set of specifications. 
       Labisia pumila  is capable of synthesizing multiple nutrients, including vitamins, minerals, fatty acids, and amino acids. Many of these constituents are expected to be preserved in the extract. The extracts of  Labisia pumila  have been shown to contain a variety of phytochemicals. The  Labisia pumila  extract comprises one or more extract components of flavonols, flavanols, flavanones, flavones, hydroxybenzoic acids, hydroxycinnamic acids, phenolic alcohols, organic acids, vitamins and vitamin precursors, saponins, alkylphenols and fatty acids. The flavonols of the present invention comprises myricetin, quercetin and rutin. The flavanols comprises catechin and epigallocatechin. The flavanones comprises naringenin. Meanwhile, the flavones comprises apigenin. The hydroxybenzoic acids comprises methyl gallate, protocatechuic acid, salicylic acid, syringic acid and vanillic acid. The hydroxycinnamic acids comprises caffeic acid and m-coumaric acid. The phenolic alcohols comprises pyrogallol and the organic acids comprises fumaric acid and succinic acid. In addition, the vitamins and vitamin precursors comprise ascorbic acid. The saponins comprises ardisiacrispin A and ardisicrenoside A. The alkylphenols comprises irisresorcinol and wherein the fatty acids comprises α-linolenic acid, linoleic acid, oleic acid, palmitic acid and stearic acid. In another embodiment of the present invention,  Labisia pumila  extract further having antioxidant properties of 65-92% of 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity and the average total phenolic content (TPC) was more than 100 mg gallic acid equivalents (GAE)/g. 
     The present invention is further explained by the following examples. The specific examples which follow illustrate the methods in which the compositions of the present invention may be prepared, components therein and their use, as well as other embodiments of the invention, but are not to be construed as limiting the invention in scope. 
     Example 3 
     Twenty-seven constituents were positively identified, including various flavonoids, phenolic acids, and fatty acids as shown in  FIG.  4   . A chromatogram of SKF7™ as shown in  FIG.  5    with validated HPLC method was used in the Quality Control for estimation of Gallic Acid (Retention time ˜3.7 min) in SKF7™. 
     Overlays are shown in  FIG.  6    (positive ionization mode) and  FIG.  7    (negative ionization mode). Overall, all three lots had similar peaks and peak intensities, indicating that the chemical composition of the extracts was very similar. The maintenance of the chemical fingerprint for each batch was provided to ensure compositional similarity and confirm that the batch of SKF7™ used in the pivotal toxicology studies presented as representative of commercial product that are safe and efficacious. 
     The average DPPH radical scavenging activity of SKF7™ (compared to ascorbic acid, set to 100%) was 65-92%. The average TPC of SKF7™ was more than 100 mg gallic acid equivalents (GAE)/g. 
     Pharmaceutical Manufacture and Formulation 
     Obesity is one of the main factors in the development of cardiovascular diseases. As a side effect the levels of cholesterol, blood pressure, blood sugar and uric acid in obese people are usually higher than those of persons of normal weight. The formulation according to the present invention has improved properties compared to other formulations existing in the art, as will be described below. A pharmaceutical formulation of the present invention comprising a  Labisia pumila  extract in admixture with a pharmaceutically acceptable carrier and excipients of the present invention for reducing the progression of health problems selected from obesity. The acceptable carrier and excipients of the present invention is maltodextrins and other excipients in the TABLE 1 below. The  Labisia pumila  extract for the pharmaceutical formulation is a  Labisia pumila  aqueous ethanolic extract. It is preferable that an oral effective dose for acceptable daily intake of 180 mg to 1500 mg per day. A delivery system for orally administering the pharmaceutical formulation of the present invention, wherein the delivery system comprises tablets, capsules, pills, granules, syrups, powders, concentrates or dry syrups. It is desired that the formulation essentially retains its physical and chemical stability, as well as its biological activity upon storage. The storage period is generally selected based on the intended shelf-life of the formulation. 
     In one embodiment of the present invention,  Labisia pumila  extract for the pharmaceutical formulation in CAPSULE FORMULATION: 320 mg capsule (Size 0)
         Active Ingredient: SKF7® ( Labisia pumila  Standardized Extract)   Gallic Acid per capsule: 3.294 mg-4.456 mg per 320 mg capsule. (HPLC assay)   Weight per Capsule: 320 mg (size 0)       

     
       
         
           
               
               
               
               
               
             
               
                 TABLE 1 
               
               
                   
               
               
                   
                   
                 Capsule 
                   
                   
               
               
                 No 
                 Ingredient 
                 Quantity 
                 Function 
                 Ratio/Proportions 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 1 
                 SKF7 ®  Labisia pumila  Extract 
                 187.5 
                 mg 
                 Active 
                 58.6% 
               
            
           
           
               
               
               
               
               
            
               
                   
                 (Standardised to Gallic Acid) 
                 (3.294 mg-4.456 mg 
                   
                   
               
               
                   
                   
                 Gallic Acid) 
               
            
           
           
               
               
               
               
               
               
            
               
                 2 
                 Tricalcium Phosphate 
                 12.8 
                 mg 
                 Glidant 
                   4% 
               
               
                 3 
                 Silicon Dioxide 
                 3.2 
                 mg 
                 Glidant 
                   1% 
               
               
                 4 
                 Premix: Microcrystalline 
                 48 
                 mg 
                 Diluent 
                     15% 
               
               
                   
                 Cellulose (97-99%) and 
               
               
                   
                 Glyceryl Monostearate (1-3%) 
               
               
                 5 
                 Microcrystalline Cellulose 
                 68.5 
                 mg 
                 Binder 
                 21.4% 
               
               
                   
                 Total 
                 320 
                 mg 
                 Total 
                  100% 
               
               
                   
               
            
           
         
       
     
     SKF7™ had undergone steps to prove its safety by complying to international standards. 
     SKF7™ was tested and in compliance of the following studies: 
     List of Safety And Toxicity Studies (OECD and ICH-GCP Compliant)
         1. Bacterial Reverse Mutation Test   2. In Vitro Mammalian Chromosome Aberration Test   3. In Vitro Mammalian Micronucleus Test   4. Mammalian Erythrocyte Micronucleus Test   5. Repeated Dose 90-Day Oral Toxicity Study In Rodents   6. Repeated Dose 1-Year Oral Chronic Toxicity Study In Rodents   7. Pharmacokinetic and Safety Clinical Study in Healthy Subjects   8. Randomised Placebo-Controlled Human Clinical Studies in Obese Subjects.       

     In another preferred embodiment of the present invention, standardised  Labisia pumila  aqueous ethanolic extract in orally effective amount characterised in that said extract for reducing the progression of health problems selected from obesity wherein the effective amount of extract orally taken ranges from 180 mg to 1500 mg per day for a period of 7 days to more than 12 months. Standardized  Labisia pumila  aqueous ethanolic extract for use wherein the effective amount of extract orally taken for acceptable daily intake is—for human in a range 180 mg to 1500 mg as per clinical In another application, a standardized  Labisia pumila  aqueous ethanolic extract for use to reduce the progression of age-related health problems selected from obesity in humans. Further application of the present invention, a standardized  Labisia pumila  aqueous ethanolic extract for use to regulate obesity and metabolic syndrome symptoms and parameters in humans. 
     The present invention is further explained by the following examples. The specific examples which follow illustrate the methods in which the compositions of the present invention may be prepared, components therein and their use, as well as other embodiments of the invention, but are not to be construed as limiting the invention in scope. 
     Example 4 
     SKF7™ is the only active ingredient used in the manufacture of the dietary supplement or pharmaceuticals. Other formulation ingredients may be added as necessary to produce the finished product. The final commercial product containing SKF7™ may use additional ingredients, such as maltodextrin. Any excipients or other additions will be approved food additives, Generally Recognized As Safe (GRAS) ingredients, or ingredients listed in “Capsule and Tablet Ingredients” of “NNFA List of Dietary Supplement Ingredients In Use Before Oct. 15, 1994.” This facility complies with current Good Manufacturing Practices (cGMP) to produce traditional medicines. Labeesity, a commercial product containing SKF7™, is approved by the Ministry of Health for sale in Malaysia as a traditional medicine. This product is in the form of capsules containing either 90 or 187.5 mg SKF7. 
     Anti-Inflammatory Treatment 
     SKF7™ and other  Labisia pumila  extracts have been shown to have anti-inflammatory activities and were shown to inhibit and suppress the above cytokines and biomarkers in multiple studies [Ahmad et al. (2020)]. SKF7™ is the only  Labisia pumila  extract that has undergone extensive safety and efficacy studies, and currently undergoing multi-sites and multi-countries Clinical Trials for Obesity under international ICH guidelines and is produced in a PIC/S GMP manufacturing facility. 
     TNF-α and IL-1 are also associated with obesity and T2DM [Alzamil (2020); Jung et al. (2014); Febbraio (2014)]. In in vivo studies, SKF7™ has been shown to have efficacy in anti-obesity models and other  Labisia pumila  extracts were also shown to have efficacy against T2DM. SKF7™ is also tested in an anti-diabetes study in vivo and is currently undergoing analysis. The relevant studies for SKF7™ and selected  Labisia pumila  extracts are explained in the following descriptions. 
     SKF7™ Data: Interleukin-1 for Anti-Inflammatory 
     In vivo study was conducted on SKF7™ treated rats, comparing to normal rat and Diet-Induced Obese (DIO) rats. SKF7™ 77.5 mg/kg, 155 mg/kg and 310 mg/kg revealed a reduction of interleukin-1 (IL-1) as compared to DIO control group by 4.5%, 10.3%, and 36.7% (P≤0.05), respectively as illustrated in  FIG.  8   . 
     Anti-Oxidant Treatment 
     Oxidative stress is highly correlated with a wide variety of inflammatory and metabolic disease states, including obesity. It is highly correlated with cumulative damage in the body done by free radicals inadequately neutralised by antioxidants. Furthermore, oxidative damage is aggravated by the decrease in antioxidant enzymes activities such as glutathione S-transferase (GST) and glutathione peroxidase (GPx) which acts as a free radical scavenger in conditions associated with oxidative stress. 
     Treatment in SKF7™ 155 mg/kg, SKF7™ 310 mg/kg and Orlistat 30 mg/kg groups revealed a significant (P≤0.01) increase in GPx as compared to DIO control group by 24.5%, 33.2% and 40.9%, respectively. Meanwhile, SKF7™ 155 mg/kg, SKF7™ 310 mg/kg and Orlistat 30 mg/kg groups induced a significant increase in GST as compared to DIO control group by 12.9% (P≤0.05), 24.1% (P≤0.01) and 10.4% (P≤0.05), respectively as illustrated in  FIG.  9   . The induction of GPx and GST are contributed to control hydroxyl radicals and thus preventing lipid peroxidation and its propagation to biological membranes causing cells injury. 
     Inhibitory Ghrelin Production Levels 
     Ghrelin levels were significantly reduced in animals treated with SKF7™ 77.5 mg/kg, SKF7™ 155 mg/kg, SKF7™ 310 mg/kg groups as compared to DIO control group by 18.0% (P 0.05), 44.5% (P≤0.01), 39.5% (P≤0.01) and, respectively as shown in  FIG.  10   . Weight loss induce significant increases in the concentration of ghrelin, a potent orexigenic hormone. Elevations in ghrelin concentration, either endogenous or exogenous, are associated with feelings of hunger and increased food intake. Interestingly, SKF7™ inhibits ghrelin production levels while inducing weight loss. Hence, no significant changes were observed in average daily feed consumption in all groups. 
     The foregoing detailed description and examples are merely illustrative of the preferred embodiments. They are by no means meant to be the exclusive description of the inventive concept hereby disclosed. It will be recognized by one of ordinary skill in the art that certain aspects of the practice of the invention are readily susceptible to modification or practice by alternative, known means. 
     REFERENCES 
     
         
         1. Abdullah, N., Hosseinpour Chermahini, D. S., Chua, L. S. and Sarmidi, M.  Labisia pumila : A review on its traditional, phytochemical and biological uses, 2013. 
         2. Hu, J., Webster, D., Cao, J. and Shao, A. (2018) The safety of green tea and green tea extract consumption in adults—Results of a systematic review.  Regulatory Toxicology and Pharmacology.  95: 412-433. 
         3. Ahmad et al. (2020) Antioxidant and Anti-inflammatory Activities of Marantodes  pumilum  (Blume) Kuntze and Their Relationship with the phytochemical content. 
         4. Alzamil (2020) Elevated Serum TNF-α Is Related to Obesity in Type 2 Diabetes Mellitus and Is Associated with Glycemic Control and Insulin Resistance. 
         5. Jung et al. (2014) Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease. 
         6. Febbraio (2014) Role of interleukins in obesity: implications for metabolic disease.